Heyholder
‹ Activism Filings

KMPHARMACEUTICAL Co.,Ltd. Periodic Report


AI summary · Not investment advice

KM Pharmaceutical sold KRW 4.0 billion in Q3 and lost KRW 0.5 billion from its main business; sales fell 8.0% from a year earlier.

Operating profit · 3 months

KRW -453.9 million

Key facts

Revenue (3 months)
KRW 4.0 billion
Net income (3 months)
KRW -704.9 million
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 4.4 billion
Revenue (year to date)
KRW 12.3 billion
Operating profit (prior-year 3 months)
KRW -809.3 million
Operating profit (year to date)
KRW -1.7 billion
Net income (prior-year 3 months)
KRW -1.0 billion
Net income (year to date)
KRW -2.3 billion

Commentary

AI commentary · Not investment advice

What happened

KM Pharmaceutical reported its third-quarter results on a standalone basis. Sales for the latest 3 months were KRW 4.03 billion. That is down 8.0% from the same period a year earlier, when sales were KRW 4.38 billion. Cumulative sales this year are KRW 12.33 billion.

In the company's terms

Operating profit (money earned from the core business) was a loss of KRW 0.45 billion for the latest 3 months. A year earlier, the 3-month loss was KRW 0.81 billion. The cumulative operating loss this year is KRW 1.70 billion.

What changes for shareholders

Net income (the final profit after taxes and all other items) was a loss of KRW 0.70 billion for the latest 3 months. A year earlier, the 3-month loss was KRW 1.02 billion. The cumulative net loss this year is KRW 2.30 billion.

Comments

No comments yet

Comments from shareholders will appear here.